Genelux’s (GNLX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Genelux (NASDAQ:GNLX) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock.

Genelux Stock Performance

NASDAQ GNLX opened at $2.54 on Monday. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $5.89. The stock has a market cap of $88.21 million, a P/E ratio of -2.67 and a beta of -1.41. The stock has a 50 day simple moving average of $4.04 and a two-hundred day simple moving average of $3.10.

Genelux (NASDAQ:GNLX) last released its earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Sell-side analysts predict that Genelux will post -0.88 earnings per share for the current year.

Institutional Trading of Genelux

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in shares of Genelux by 39.7% in the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after buying an additional 89,854 shares during the last quarter. Marshall Wace LLP lifted its stake in Genelux by 51.4% in the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock worth $368,000 after purchasing an additional 52,958 shares in the last quarter. LPL Financial LLC increased its stake in Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after acquiring an additional 39,516 shares during the last quarter. LifeSteps Financial Inc. increased its holdings in shares of Genelux by 11.1% in the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after buying an additional 8,715 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Genelux in the 3rd quarter worth approximately $59,000. Institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.